Greater New York Ending Disparities and Inequities in CKD Leadership Summit
Join us October 19, 2023 for a 2-hour summit where we will convene and discuss solutions compiled from the 4 workgroups. Please register to attend.
About the Initiative
Approximately 2,220,000 adults in Greater New York are affected by CKD; and approximately 266,000 adults are aware of it. As part of a national NKF Collective Impact strategy, Greater New York stakeholders are implementing a roadmap to drive a cultural shift in primary care - toward increasing the early diagnosis and management of CKD, especially in communities disproportionately burdened by CKD.
Collective Impact Process
Using a multi-phase stakeholder engagement process, NKF will create the conditions for Collective Impact - influential champions, adequate financial resources, and a sense of urgency for change1- to drive change in Greater New York.
Learning and Action Workgroups
Through a series of facilitated discussions, health care and public health leaders will identify barriers and solutions to improve CKD awareness, detection, and management in Greater New York, and especially tools and strategies that can be implemented within stakeholders’ own institutions. Learning and action workgroups will support increased awareness and action amongst the participants. The four workgroups will convene covering the following topics:
Clinical Considerations for CKD in Primary Care
- Goal: To discuss strategies and approaches that can be employed to improve CKD recognition and care in primary care settings.
- Background: A large, national study illustrated that less than 12% of people with CKD were diagnosed in primary care.2 This included as many as 40% of people whose kidneys required specialty care. With the advent of new therapies demonstrated to slow or stop the progression of CKD, there is a very real opportunity to improve quality of care for people with CKD across the entire spectrum of disease.
Engaging Community and Community-Based Solutions
- Goal: To develop strategies to advance CKD awareness through community engagement and to ensure that health care providers are aware of the community resources available to delay CKD progression.
- Background: In the US today, only 10% of people with laboratory evidence of CKD know that they have kidney disease.3 Improved patient awareness, engagement, and Self-Management are vital to successfully slowing CKD progression. As diabetes and hypertension play significant roles in the development of CKD, working with community organizations that support people with chronic disease can be an important step toward raising public awareness of CKD among those at risk for CKD.
Wellness and Prevention (CKD Population Health)
- Goal: To develop a strategy to incorporate CKD testing and diagnosis into wellness and prevention practices within the employer/commercial health plans, and the broader community.
- Background: To date, almost 90% of people living with CKD remain undiagnosed in the population and the majority will not receive guideline recommended annual testing.5 This breakout session will discuss the strategies that can be developed and employed to ensure that CKD testing and diagnosis are included as part of the wellness and prevention services, including corporate programs, diabetes prevention activities, etc., that are available in the Greater New York area.
Policy, Payment, and Quality Measurement
- Goal: To develop a strategy to streamline CKD testing in primary care from a policy and payment perspective.
- Background: In July 2020, the NCQA released the Kidney Health Evaluation for Adults with Diabetes HEDIS measure (KHE).4 This measure assesses the percentage of people with diabetes that receive both tests for CKD during the course of a year. When tested against over 70 claims datasets, this measure was achieved in only 35% of cases. This measure began collecting data for public reporting in October 2021.
Check back soon for a summary of our roadmap strategies, expected October, 2023.
Meet Our Summit Co Chairs:
Antonia Eyssallenne, MD
Senior Medical Advisor
NYC Department of Health and Mental Hygiene
Susan Beane, MD FACP
Executive Medical Director
Healthfirst Partnerships - Medical Outcomes
Learn More and Join the Collective Impact Effort
- Hanley Brown, F. Kania, J. and Kramer, M. Channeling Change: Making Collective Impact Work. Stanford Social Innovation Review. 2012. https://doi.org/10.48558/2T4M-ZR69
- Szczech, Lynda A., et al. “Primary Care Detection of Chronic Kidney Disease in Adults with Type-2 Diabetes: The ADD-CKD Study (Awareness, Detection and Drug Therapy in Type 2 Diabetes and Chronic Kidney Disease).” Public Library of Science, 26 Nov. 2014. https://doi.org/10.1371/journal.pone.0110535
- “Chronic Kidney Disease (CKD) Surveillance System: Awareness.” Centers for Disease Control and Prevention. https://nccd.cdc.gov/ckd/detail.aspx?QNum=Q97#refreshPosition
- Brock, Matt. “Kidney Health: A New HEDIS Measure.” NCQA Blog, 16 Jul. 2020. https://blog.ncqa.org/kidneyhealth/
- “Chronic Kidney Disease in the United States, 2021.” Centers for Disease Control and Prevention, 4 Mar. 2021. https://www.cdc.gov/kidneydisease/pdf/Chronic-Kidney-Disease-in-the-US-2021-h.pdf